Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
复制标题
DOI：
10.1172/jci0215001
复制
发表时间：
2002-05-01
影响因子：
15.9
通讯作者：
Shulman, GI
中科院分区：
文献类型：
--
作者：
Petersen, KF;Oral, EA;Shulman, GI
脂肪营养不良是一种罕见的疾病，其特征是选择性地丢失皮下和内脏脂肪，并与高甘油三酯血症、肝肿大和糖代谢紊乱有关。最近有研究表明，慢性瘦素治疗可以改善这些异常。在这里，我们显示慢性瘦素治疗改善严重胰岛素抵抗脂肪营养不良患者的胰岛素刺激的肝脏和外周葡萄糖代谢。胰岛素作用的这种改善与肝脏和肌肉甘油三酯含量的显著降低有关。这些数据表明，瘦素可能是一种重要的新疗法，可以逆转脂肪营养不良患者严重的肝脏和肌肉胰岛素抵抗以及相关的肝脏脂肪变性。
Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.